Treatment Improves Patient-Reported Outcomes in Adults With Psoriatic Arthritis

Patients with active psoriatic arthritis treated with secukinumab demonstrated early, clinically meaningful improvement in patient-reported outcomes compared with placebo irrespective of previous tumor necrosis factor (TNF) inhibitor use. Researchers published findings from a post hoc analysis in The Lancet Rheumatology.

“These results indicate that secukinumab provides comprehensive improvement for patients with psoriatic arthritis, regardless of previous therapy,” wrote lead and corresponding author Vibeke Strand, MD, of the Stanford University Division of Immunology and Rheumatology in Palo Alto, California, and coauthors.

The analysis focused on a slate of patient-reported assessments from the phase 3 FUTURE 5 trial, which showed both clinical and radiographical efficacy of secukinumab. The trial randomized adults with moderate-to-severe psoriatic arthritis to secukinumab 300 mg, secukinumab 150 mg, secukinumab 150 mg no loading dose (NL), or placebo weekly from baseline to week 4 and every 4 weeks afterward.

Except for the mental component summary of the 36-item Short Form Health Survey (SF-36), all patient-reported outcomes at week 16 showed significant least-squares mean changes for all secukinumab groups compared with placebo, according to study authors.

Specifically, compared with placebo:

• patient global assessments of disease activity decreased an additional 12.2 points with secukinumab 300 mg, 8.22 points with secukinumab 150 mg, and 8.3 points with secukinumab 150 mg NL;
• pain visual analog scale scores decreased an additional 14.3 with secukinumab 300 mg, 11.5 with secukinumab 150 mg, and 11.3 with secukinumab 150 mg NL;
• Health Assessment Questionnaire Disability Index scores decreased an additional .33 with secukinumab 300 mg, .23 with secukinumab 150 mg, and .24 with secukinumab 150 mg NL; and
• Functional Assessment of Chronic Illness Therapy Fatigue scores decreased an additional 4.8 with secukinumab 300 mg, 4.2 with secukinumab 150 mg, and 3.5 with secukinumab 150 mg NL.

Results were similar when researchers looked at the proportion of patients with improvement at week 16. For most patient-reported outcomes, and regardless of TNF inhibitor use, rates were higher with secukinumab than placebo, with one exception: the mental component summary of the SF-36.

Reference:
Strand V, Kaeley GS, Bergman MJ, et al. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial. Lancet Rheumatol. 2022;4(3):e208-e219. doi:10.1016/S2665-9913(21)00354-4